A Cambridge biotech is embarking on its largest endeavor yet: launching two mid- and late-stage studies for its microbiome therapeutics for gastrointestinal disorders. Now it has $106.5 million to see it through to completion.
A Cambridge biotech is embarking on its largest endeavor yet: launching two mid- and late-stage studies for its microbiome therapeutics for gastrointestinal disorders. Now it has $106.5 million to see it through to completion.
